Literature DB >> 2605394

Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies.

A Novogrodsky, K H Stenzel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2605394      PMCID： PMC1807790     

Source DB:  PubMed          Journal:  Bull N Y Acad Med        ISSN： 0028-7091


× No keyword cloud information.
  11 in total

1.  Induction of lymphocyte transformation by sequential treatment with neuraminidase and galactose oxidase.

Authors:  A Novogrodsky; E Katchalski
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

2.  Membrane site modified on induction of the transformation of lymphocytes by periodate.

Authors:  A Novogrodsky; E Katchalski
Journal:  Proc Natl Acad Sci U S A       Date:  1972-11       Impact factor: 11.205

3.  Cellular and growth factor requirements for activation of human T lymphocytes by neuraminidase and galactose oxidase-treated lymphoid cells.

Authors:  S Lipkowitz; A L Rubin; K H Stenzel; A Novogrodsky
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

4.  Anti-tumor properties of lymphocytes activated by the oxidizing mitogens.

Authors:  J Wang; M Suthanthiran; A Walle; M Lagman; R Schwartz; V Murthi; A Novogrodsky; K H Stenzel
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

5.  Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

Authors:  J Wang; A Walle; B Gordon; A Novogrodsky; M Suthanthiran; A L Rubin; H Morrison; R T Silver; K H Stenzel
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

6.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Authors:  M T Lotze; E A Grimm; A Mazumder; J L Strausser; S A Rosenberg
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

9.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.